# USANA HEALTH SCIENCES, INC. (USNA) · Edgar & Edgarette company card

> Usana Health Sciences (USNA) grew revenue 8.3% in FY2026 to $925 million, operating margin 4.0% against a 0.7% median for medicinal chemicals & botanical products, equity 71.8% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 896264 · fiscal year ended 2026-01-03 · 5 audited years read · [page](https://www.pops4.com/boards/company/USNA) · [JSON](https://www.pops4.com/boards/company/USNA.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $925M |
| Revenue growth, 1 year | 8.3% |
| Revenue growth per year | -6.0% |
| Operating margin | 4.0% (prior year 7.8%) |
| Net margin | 1.2% |
| Operating cash flow | $22M |
| Capital spending | $14M |
| Free cash flow | $9M |
| Cash | $158M |
| Long-term debt | — |
| Total assets | $743M |
| Total equity | $533M |
| Equity ÷ assets | 71.8% |
| Return on equity | 2.2% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: 7.37 (safe zone)
- Piotroski F: 7 of 9 (solid)
- Health Harbor boat: New ship · no warning signs
- Cash Compass: In between · no clear cash pattern yet

## Edgarette's reading

Exposure: revenue $925.3M (FY2026). Experience: revenue up 8.3% on the year, down 6.0% a year over 4 years; operating margin 4.0%, down from 7.8%. Soundness: equity 71.8% of assets, return on equity 2.2%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $789.3M and $1.1B next year (method v4.1: its own 5-year record of growth weighed at 57% against $100M–1B filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $725.2M to $1.2B. A statistical range, not company guidance. Against peers (10 filers, $50M+ revenue, medicinal chemicals & botanical products): operating margin 4.0% against a 0.7% median; growth 8.3% against 1.7%.

Range logged 2026-10-06, receipt 13114a3fc09347f5, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 1, latest 2026-01-08 ([filing](https://www.sec.gov/Archives/edgar/data/896264/000089626426000002/0000896264-26-000002-index.htm))

## Recent filings

- 10-Q · filed 2026-11-12 · [filing](https://www.sec.gov/Archives/edgar/data/896264/000089626426000070/0000896264-26-000070-index.htm)
- 8-K · filed 2026-11-03 · 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/896264/000089626426000064/0000896264-26-000064-index.htm)
- 8-K · filed 2026-10-05 · 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/896264/000089626426000060/0000896264-26-000060-index.htm)
- 10-Q · filed 2026-08-13 · [filing](https://www.sec.gov/Archives/edgar/data/896264/000089626426000056/0000896264-26-000056-index.htm)
- 8-K · filed 2026-08-04 · 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/896264/000089626426000050/0000896264-26-000050-index.htm)
- 8-K · filed 2026-05-20 · 5.07 Submission of Matters to a Vote of Security Holders · [filing](https://www.sec.gov/Archives/edgar/data/896264/000089626426000036/0000896264-26-000036-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0000896264.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=896264

## Cite

POPS4, Edgar & Edgarette: USANA HEALTH SCIENCES, INC. (USNA) company card, from the company's own SEC filings, accessed 2026-11-19, https://www.pops4.com/boards/company/USNA. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.

